OPTIMA Supports Therapy De-escalation in High-Risk Breast Cancer Sharon Worcester June 09, 2026

https://www.medscape.com/viewarticle/optima-supports-therapy-de-escalation-high-risk-breast-2026a1000j6x About two thirds of patients with high-risk ER-positive, HER2-negative early breast cancer had similar outcomes whether or not they received chemotherapy alongside endocrine therapy, suggesting many may be able to safely avoid chemotherapy, according to findings from the phase 3 OPTIMA trial.